雄激素受体信号抑制剂对mCRPC患者[177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-I&T治疗吸收剂量的影响:剂量学结果
本单中心回顾性分析纳入50例mCRPC患者,比较[177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-I&T放射配体治疗联合ARSi(联合组,n=25)与单药治疗(对照组,n=25)的剂量学差异。结果显示联合ARSi未显著提高肿瘤吸收剂量,[177Lu]Lu-PSMA-I&T联合组肾脏和肝脏吸收剂量显著低于对照组。
要点
- 联合ARSi未显著提高[177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-I&T的肿瘤吸收剂量。
- [177Lu]Lu-PSMA-I&T联合组肾脏和肝脏吸收剂量显著低于单药组。
- 需更大样本前瞻性研究验证ARSi对肿瘤吸收剂量的影响。
核心结论
- 在该试点队列中,同期ARSi治疗未显著提高接受[177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-I&T RLT患者的肿瘤吸收剂量。
研究设计与样本
- 单中心回顾性分析纳入50例mCRPC患者,接受首周期[177Lu]Lu-PSMA-617(n=37)或[177Lu]Lu-PSMA-I&T(n=13)RLT±同期ARSi(阿比特龙或恩扎卢胺)治疗。
- 患者分为联合组(RLT+ARSi,n=25)和对照组(仅RLT,n=25)。
- 于首周期给药后24h(+CT)、48h和72h行定量SPECT成像,肿瘤病灶基于24h SPECT图像分割,危及器官(肾、脾、肝)在对应CT上勾画。
- 采用单指数曲线拟合结合局部密度缩放计算吸收剂量,并按每种放射性配体分别评估剂量学结果。
主要发现
- 共分析148个肿瘤病灶(每例患者中位3个病灶)。
- [177Lu]Lu-PSMA-617联合组与对照组中位肿瘤吸收剂量相当(2.1±4.0 Gy/GBq vs 1.5±1.7 Gy/GBq,p=0.24)。
- [177Lu]Lu-PSMA-I&T联合组与对照组中位肿瘤吸收剂量相当(1.2±1.2 Gy/GBq vs 1.2±3.5 Gy/GBq,p=0.21)。
- [177Lu]Lu-PSMA-617两组危及器官吸收剂量相当:肾脏0.28±0.11 vs 0.27±0.13 Gy/GBq(p=0.90);脾0.05±0.05 vs 0.06±0.05 Gy/GBq(p=0.75);肝0.08±0.03 vs 0.07±0.04 Gy/GBq(p=0.75)。
- [177Lu]Lu-PSMA-I&T联合组肾脏和肝脏吸收剂量显著低于对照组:肾脏0.21±0.10 vs 0.30±0.08 Gy/GBq(p=0.01);肝0.02±0.01 vs 0.04±0.01 Gy/GBq(p=0.01);脾0.02±0.02 vs 0.04±0.03 Gy/GBq(p=0.20)。
临床怎么用
- 对于接受[177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-I&T RLT的mCRPC患者,同期使用ARSi未显示提高肿瘤吸收剂量的获益。
- [177Lu]Lu-PSMA-I&T联合ARSi时肾脏和肝脏吸收剂量较低,但需结合临床进一步验证。
局限性
- 本为单中心回顾性试点队列,样本量有限(50例)。
- 需更大样本前瞻性研究评估同期ARSi对mCRPC肿瘤病灶吸收剂量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen receptor signaling inhibitors (ARSi) have significantly improved clinical outcomes in men with prostate cancer (PCa). Preliminary data suggest the potential for ARSi to enhance PSMA expression in patients with mCRPC. In this analysis, we present preliminary dosimetry results from mCRPC patients treated with either [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T radioligand therapy (RLT) in combination with ARSi compared to a Control Group of patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T monotherapy. METHODS: This retrospective analysis was performed at a single center, including 50 patients diagnosed with mCRPC who underwent their first cycle of [177Lu]Lu-PSMA-617 (n = 37) or [177Lu]Lu-PSMA-I&T (n = 13) RLT ± concomitant ARSi treatment (abiraterone or enzalutamide). Patients were divided into a Combination Group (RLT + ARSi, n = 25) and a Control Group (RLT only, n = 25). Quantitative SPECT imaging was performed at 3 time points: 24 h (+ CT), 48 h, and 72 h post-administration of the initial cycle of RLT. Tumor lesions were segmented using the 24 h SPECT images, while organs-at-risk (kidney, spleen, liver) were delineated on the corresponding CT. Absorbed doses were calculated by applying a mono-exponential curve fit, incorporating local density scaling. Dosimetry results were evaluated separately for each radioligand. RESULTS: Overall, 148 tumor lesions were included in this analysis (median 3 lesions per patient). The median tumor absorbed dose was comparable between the Combination Group and the Control Group: [177Lu]Lu-PSMA-617 (2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq, p = 0.24) and [177Lu]Lu-PSMA-I&T (1.2 ± 1.2 Gy/GBq vs 1.2 ± 3.5 Gy/GBq, p = 0.21). Furthermore, the median absorbed dose in organs-at-risk was comparable between the two groups in [177Lu]Lu-PSMA-617: Kidneys: 0.28 ± 0.11 Gy/GBq vs 0.27 ± 0.13 Gy/GBq, p = 0.90; Spleen: 0.05 ± 0.05 Gy/GBq vs 0.06 ± 0.05 Gy/GBq, p = 0.75; Liver: 0.08 ± 0.03 Gy/GBq vs 0.07 ± 0.04 Gy/GBq, p = 0.75). A statistically significant difference was noted in kidneys and liver for [177Lu]Lu-PSMA-I&T: Kidneys: 0.21 ± 0.10 Gy/GBq vs 0.30 ± 0.08 Gy/GBq, p = 0.01; Spleen: 0.02 ± 0.02 Gy/GBq vs 0.04 ± 0.03 Gy/GBq, p = 0.20; Liver: 0.02 ± 0.01 Gy/GBq vs 0.04 ± 0.01 Gy/GBq, p = 0.01. CONCLUSION: In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.
引用
- Zahner J, Delker A, Ells Z, et al. Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. Eur J Nucl Med Mol Imaging. 2026. PMID: 42274762. doi:10.1007/s00259-026-07967-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。